Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion To Commercialize Novartis’s COPD Products In US

Executive Summary

Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.

Advertisement

Related Content

Sumitomo Dainippon Shores Business/Pipeline Ahead Of Latuda Cliff
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Clinical Evidence Concern Over New COPD Update
GOLD Pushes LABA/LAMA Class In New COPD Treatment Update
Novartis's FLAME Rockets LAMA/LABAs Into COPD Limelight At GSK's Expense

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel